BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 3, 2015, Pages 462-472

  Faraoni, Isabella ^a,b   Compagnone, Mirco ^b   Lavorgna, Serena ^a,b   Angelini, Daniela Francesca ^b   Cencioni, Maria Teresa ^b   Piras, Eleonora ^b   Panetta, Paola ^a,b   Ottone, Tiziana ^a,b   Dolci, Susanna ^a   Venditti, Adriano ^a   Graziani, Grazia ^a   Lo Coco, Francesco ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Acute myeloid leukemia; BRCA1; H2AX; Olaparib; PARP inhibitor; PARP1

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CD135 ANTIGEN; CD34 ANTIGEN; HISTONE H2AX; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NUCLEOPHOSMIN; OLAPARIB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; RAD51 PROTEIN; BRCA1 PROTEIN, HUMAN; ENZYME INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CELL DEATH; CHROMOSOME 11Q; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; U937 CELL LINE;

BRCA1 PROTEIN; CHROMOSOME DELETION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; TUMOR MARKERS, BIOLOGICAL; U937 CELLS;

EID: 84920089489     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.12.001     Document Type: Article

References (48)

1. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., Dombret H., Fenaux P., Grimwade D., Larson R.A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G.J., Sanz M.A., Sierra J., Tallman M.S., Löwenberg B., Bloomfield C.D. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. O'Donnell M.R., Abboud C.N., Altman J., Appelbaum F.R., Arber D.A., Attar E., Borate U., Coutre S.E., Damon L.E., Goorha S., Lancet J., Maness L.J., Marcucci G., Millenson M.M., Moore J.O., Ravandi F., Shami P.J., Smith B.D., Stone R.M., Strickland S.A., Tallman M.S., Wang E.S., Naganuma M., Gregory K.M. Acute myeloid leukemia. J. Natl. Compr. Cancer Netw. 2012, 10:984-1021.
3. Hottiger M.O., Hassa P.O., Lüscher B., Schüler H., Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35:208-219.
4. Sousa F.G., Matuo R., Soares D.G., Escargueil A.E., Henriques J.A., Larsen A.K., Saffi J. PARPs and the DNA damage response. Carcinogenesis 2012, 33:1433-1440.
5. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
6. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. (Erratum in: Nature 2007; 447: 346).
7. De Lorenzo S.B., Patel A.G., Hurley R.M., Kaufmann S.H. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front. Oncol. 2013, 3:228.
8. Shah G.M., Robu M., Purohit N.K., Rajawat J., Tentori L., Graziani G. PARP inhibitors in cancer therapy: magic bullets but moving targets. Front. Oncol. 2013, 3:279.
9. Drew Y., Mulligan E.A., Vong W.T., Thomas H.D., Kahn S., Kyle S., Mukhopadhyay A., Los G., Hostomsky Z., Plummer E.R., Edmondson R.J., Curtin N.J. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 2011, 103:334-346.
10. Daemen A., Wolf D.M., Korkola J.E., Griffith O.L., Frankum J.R., Brough R., Jakkula L.R., Wang N.J., Natrajan R., Reis-Filho J.S., Lord C.J., Ashworth A., Spellman P.T., Gray J.W., van't Veer L.J. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res. Treat. 2012, 135:505-517.
11. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
12. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tutt A.N., Zdzienicka M.Z., Smith G.C., Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66:8109-8115.
13. Haince J.F., Kozlov S., Dawson V.L., Dawson T.M., Hendzel M.J., Lavin M.F., Poirier G.G. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J. Biol. Chem. 2007, 282:16441-16453.
14. Aguilar-Quesada R., Muñoz-Gámez J.A., Martín-Oliva D., Peralta A., Valenzuela M.T., Matínez-Romero R., Quiles-Pérez R., Menissier-de Murcia J., de Murcia G. Ruiz de Almodóvar M, Oliver FJ. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol. Biol. 2007, 8:29.
15. Weston V.J., Oldreive C.E., Skowronska A., Oscier D.G., Pratt G., Dyer M.J., Smith G., Powell J.E., Rudzki Z., Kearns P., Moss P.A., Taylor A.M., Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010, 116:4578-4587.
16. Haince J.F., McDonald D., Rodrigue A., Déry U., Masson J.Y., Hendzel M.J., Poirier G.G. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem. 2008, 283:1197-1208.
17. Oplustilova L., Wolanin K., Mistrik M., Korinkova G., Simkova D., Bouchal J., Lenobel R., Bartkova J., Lau A., O'Connor M.J., Lukas J., Bartek J. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012, 11:3837-3850.
18. Gaymes T.J., Mohamedali A.M., Patterson M., Matto N., Smith A., Kulasekararaj A., Chelliah R., Curtin N., Farzaneh F., Shall S., Mufti G.J. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly(ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013, 98:1397-1406.
19. Gottipati P., Vischioni B., Schultz N., Solomons J., Bryant H.E., Djureinovic T., Issaeva N., Sleeth K., Sharma R.A., Helleday T. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010, 70:5389-5398. (Erratum in: Cancer Res 2011; 71: 2803).
20. Höglund A., Strömvall K., Li Y., Forshell L.P., Nilsson J.A. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle 2011, 10:3598-3607.
21. Gaymes T.J., Shall S., MacPherson L.J., Twine N.A., Lea N.C., Farzaneh F., Mufti G.J. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 2009, 94:638-646.
22. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
23. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
24. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., Wardley A., Mitchell G., Earl H., Wickens M., Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
25. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12:852-861.
26. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012, 366:1382-1392.
27. Bundred N., Gardovskis J., Jaskiewicz J., Eglitis J., Paramonov V., McCormack P., Swaisland H., Cavallin M., Parry T., Carmichael J., Dixon J.M. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Investig. New Drugs 2013, 31:949-958.
28. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
29. Noguera N.I., Ammatuna E., Zangrilli D., Lavorgna S., Divona M., Buccisano F., Amadori S., Mecucci C., Falini B., Lo-Coco F. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005, 19:1479-1482. (Erratum in: Leukemia 2007; 21: 1134).
30. Samol J., Ranson M., Scott E., Macpherson E., Carmichael J., Thomas A., Cassidy J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Investig. New Drugs 2012, 30:1493-1500.
31. Yamamoto N., Nokihara H., Yamada Y., Goto Y., Tanioka M., Shibata T., Yamada K., Asahina H., Kawata T., Shi X., Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012, 103:504-509.
32. Murai J., Huang S.Y., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012, 72:5588-5599.
33. Pepponi R., Graziani G., Falcinelli S., Vernole P., Levati L., Lacal P.M., Pagani E., Bonmassar E., Jiricny J., D'Atri S. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis 2001, 22:1131-1137.
34. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074. (Erratum in: N Engl J Med 2013; 369: 98).
35. Cai F., Ge I., Wang M., Biskup E., Lin X., Zhong X. Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells. Tumour Biol. 2014, 35:3839-3844.
36. Prensner J.R., Chen W., Iyer M.K., Cao Q., Ma T., Han S., Sahu A., Malik R., Wilder-Romans K., Navone N., Logothetis C.J., Araujo J.C., Pisters L.L., Tewari A.K., Canman C.E., Knudsen K.E., Kitabayashi N., Rubin M.A., Demichelis F., Lawrence T.S., Chinnaiyan A.M., Feng F.Y. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014, 74:1651-1660.
37. Scardocci A., Guidi F., D'Alo' F., Gumiero D., Fabiani E., Diruscio A., Martini M., Larocca L.M., Zollino M., Hohaus S., Leone G., Voso M.T. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br. J. Cancer 2006, 95:1108-1113.
38. Moskwa P., Buffa F.M., Pan Y., Panchakshari R., Gottipati P., Muschel R.J., Beech J., Kulshrestha R., Abdelmohsen K., Weinstock D.M., Gorospe M., Harris A.L., Helleday T., Chowdhury D. MiR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 2011, 41:210-220.
39. Hegan D.C., Lu Y., Stachelek G.C., Crosby M.E., Bindra R.S., Glazer P.M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2201-2206.
40. Nowsheen S., Cooper T., Bonner J.A., LoBuglio A.F., Yang E.S. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 2012, 72:4796-4806.
41. Murai J., Huang S.Y., Renaud A., Zhang Y., Ji J., Takeda S., Morris J., Teicher B., Doroshow J.H., Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 2014, 13:433-443.
42. Meng X.W., Koh B.D., Zhang J.S., Flatten K.S., Schneider P.A., Billadeau D.D., Hess A.D., Smith B.D., Karp J.E., Kaufmann S.H. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J. Biol. Chem. 2014, 289:20543-20558.
43. Tentori L., Ricci-Vitiani L., Muzi A., Ciccarone F., Pelacchi F., Calabrese R., Runci D., Pallini R., Caiafa P., Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 2014, 14:151.
44. Glénisson M., Vacher S., Callens C., Susini A., Cizeron-Clairac G., Le Scodan R., Meseure D., Lerebours F., Spyratos F., Lidereau R., Bièche I. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer 2012, 3:63-70.
45. Ossovskaya V., Koo I.C., Kaldjian E.P., Alvares C., Sherman B.M. Upregulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010, 1:812-821.
46. Wu J., Clingen P.H., Spanswick V.J., Mellinas-Gomez M., Meyer T., Puzanov I., Jodrell D., Hochhauser D., Hartley J.A. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin. Cancer Res. 2013, 19:721-730.
47. Redon C.E., Weyemi U., Parekh P.R., Huang D., Burrell A.S., Bonner W.M. γ-H2AX and other histone post-translational modifications in the clinic. Biochim. Biophys. Acta 2012, 1819:743-756.
48. Jacoby M.A., De Jesus Pizarro R.E., Shao J., Koboldt D.C., Fulton R.S., Zhou G., Wilson R.K., Walter M.J. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia 2014, 28:1242-1251.